Sponsor Pipeline

TILT Biotherapeutics Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
4
Active Trials
0
Recruiting
4
Disease Areas
Active Trials by Phase
Phase 1/2
1
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT05271318 Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or… Platinum-refractory Ovarian Carcinoma Active, Not Recruiting
Phase 1
NCT05222932 Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or… Melanoma Active, Not Recruiting
NCT06125197 Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small… Lung Cancer Active, Not Recruiting
NCT06961786 TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy… Metastatic Melanoma Active, Not Recruiting
Disease Areas
Get alerts when TILT Biotherapeutics Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free